Antibodies to SS‐A/Ro‐52kD and centromere in autoimmune liver disease: a clue to diagnosis and prognosis of primary biliary cirrhosis

Granito, Alessandro; Muratori, Paolo; Pappas, Georgios; Cassani, F.; Worthington, J.; Ferri, Silvia; Quarneti, Chiara; Cipriano, V.; Molo, Chiara De; Lenzi, Marco; Chapman, Roger W.; Bianchi, Francesco

doi:10.1111/j.1365-2036.2007.03433.x

Cited by 86 publications

(52 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Stinton et al 16) determined the prevalences of different autoantibodies among 109 patients with PBC (including 6 patients negative for AMA) using LIA (82% for AMA -M2, 73% for M2 -3E, 27% for anti -Sp100 antibody, 17% for anti -PML antibody, 27% for anti -gp210 antibody, 32% for anti -Ro -52 antibody and 11% for ACA), which were different from those observed in the present study (65% for AMA -M2, 77.5% for M2 -3E, 13.8% for anti -Sp100 antibody, 8.7% for anti -PML antibody, 40.0% for anti -gp210 antibody, 27.5% for anti -Ro -52 antibody and 32.5% for ACA). The reported prevalences of these autoantibodies vary among studies : 75 -96% for AMA -M2 17) , 57% for M2 -3E 18) , 20 -30% for anti -Sp100 antibody 17,19,20) , 19% for anti -PML antibody 21) , 17 -25% for antigp210 antibody 17,22) , 25 -28% for anti -Ro -52 antibody 23,24) , and 10 -30% for ACA 25 -27) . This variability may reflect differences in target populations, such as racial difference, timing of sample collection and other variables among institutions.…”

Section: Discussionmentioning

confidence: 99%

“…The anti -Ro -52 antibody is a type of anti -SS -A/Ro antibody that has been detected in many autoimmune diseases, including Sjogren's syndrome 36) . Granito et al reported that the population of PBC patients positive for anti -Ro -52 antibody includes significantly more patients with advanced histological stage and high serum bilirubin levels than dose the negative population 23) . In the present study, both the subset of patients positive for anti -gp210 antibody and that of patients positive for anti -Ro -52 antibody included significantly more patients with jaundice than did the subsets of patients negative for these antibodies, being consistent with results of previous studies.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Autoantibodies by Line Immunoassay in Patients With Primary Biliary Cirrhosis

Saito¹,

Takahashi²,

Abe³

et al. 2012

Fukushima J. Med. Sci.

View full text Add to dashboard Cite

: Objectives : We attempted to measure multiple autoantibodies simultaneously using line immunoassay (LIA) in patients with primary biliary cirrhosis (PBC) with or without anti -mitochondrial antibody (AMA) and patients with PBC -autoimmune hepatitis (AIH) overlap, and we examined the clinical significance of measuring these autoantibodies. Methods : The study population consisted of 80 patients with PBC (including 12 AMA -negative patients), 16 patients with PBC -AIH overlap and 40 patients with AIH as controls. Nine antibodies (AMA -M2, M2 -3E, Sp100, PML, gp210, Ro -52, LKM -1, LC -1 and SLA/LP) were detected by LIA, and AMA -M2 and anti -centromere antibody (ACA) were detected by ELISA. We examined the relationship between these autoantibodies and clinical findings. Results : The positive prevalence of each autoantibody and ACA in the PBC group, as determined by LIA, was as follows : 13.8% for anti -Sp100, 8.7% for anti -PML, 40% for anti -gp210 and 27.5% for anti -Ro -52 antibodies and 32.5% for ACA. In the PBC -AIH overlap group, the prevalence of anti -gp210 antibody (68.7%) and that of anti -Ro -52 antibody (81.2%) were significantly higher than those in the PBC and AIH groups. Only a few patients were positive for 2 or more autoantibodies. Nine patients were determined to be negative for all autoantibodies by LIA, of whom 7 were positive for ACA. Patients positive for anti -gp210 antibody included more patients classified as stage 4 on histology than did the negative group. Those positive for ACA included more patents with varices than did the negative group. Conclusion : LIA can measure multiple autoantibodies simultaneously and thus is considered useful in diagnosing PBC and PBC -AIH overlap. In addition, ACA is a useful marker for identifying AMA -negative PBC.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Autoantibodies by Line Immunoassay in Patients With Primary Biliary Cirrhosis

Saito¹,

Takahashi²,

Abe³

et al. 2012

Fukushima J. Med. Sci.

View full text Add to dashboard Cite

show abstract

“…ANA is reported in 8%-77% of the PSC patients (Table 1). No particular ANA subspecificities seem to predominate; anti-dsDNA has been reported in 3%-29% [61,78,87,111] , anti-ENA in 4%-12% [78,111,112] , anti SSA/B in 1%-28% [78,87] and anti-RNP, anti-SCL70, anti-Sm and anti-ssDNA in a minority of patients [87] . SMAs have been reported in 0%-83% of PSC patients (Table 1) but the prevalence is also high in AIH, various malignancies and infections [107] .…”

Section: Antinuclear (Anas) and Smooth Muscle Antibodies (Smas)mentioning

confidence: 99%

Autoantibodies in primary sclerosing cholangitis

Hov¹,

Boberg²,

Karlsen³

2008

WJG

150

100

View full text Add to dashboard Cite

The aetiology of primary sclerosing cholangitis (PSC) is not known and controversy exists as to whether PSC should be denominated an autoimmune disease. A large number of autoantibodies have been detected in PSC patients, but the specificity of these antibodies is generally low, and the frequencies vary largely between different studies. The presence of autoantibodies in PSC may be the result of a nonspecific dysregulation of the immune system, but the literature in PSC points to the possible presence of specific antibody targets in the biliary epithelium and in neutrophil granulocytes. The present review aims to give an overview of the studies of autoantibodies in PSC, with a particular emphasis on the prevalence, clinical relevance and possible pathogenetic importance of each individual marker.

show abstract

“…The presence of anti-Ro52 antibodies has been reported in a wide variety of autoimmune diseases, particularly in myositis, scleroderma and autoimmune liver diseases [9,10], and have been associated with nonautoimmune diseases such as viral infections or neoplastic diseases [11].…”

Section: Introductionmentioning

confidence: 99%